Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VLX-1005 in Healthy Subjects
NCT04783545Phase 1Completed
- Sponsor
- Veralox Therapeutics
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VLX-1005 in heparin-induced thrombocytopenia (HIT) (4 arms), sponsored by Veralox Therapeutics. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Number of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements and 2 more. Started Mar 2021; status: completed.
02
Drugs
VLX-1005
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT04783545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783545.